We need answer legal/regulatory plan. Need think through. Need produce final ordered plan addressing points. Need be precise. Need not overdo but include exact stop etc. Need include "without assuming unknown 62-subject scope." We need likely explain: stop new enrollment and nonurgent research interventions under defective form for all subjects? Actually when discovered and scope unknown: sponsor must immediately suspend new enrollment and nonurgent research interventions at all sites until determines which form? Let's parse rule 2: "When a sponsor discovers that a consent form omitted a material risk, it must immediately stop new enrollment and nonurgent research interventions under the defective form until an ethics board approves corrected materials." Facts: known omitted in 4.2; scope unknown. There are subjects with unknown versions. Need determine who is under defective form. But to avoid any affected subject undergoing nonurgent intervention under defective consent? Rule says under defective form. Unknown forms could be 4.2; not yet verified. Therefore likely hold all nonurgent research interventions where consent version not confirmed as valid? More exact: Immediately halt all new enrollment and all nonurgent study interventions whose consent version is not confirmed to be 4.1/4.3; if confirmed 4.1/4.3 can continue? But rule says stop under defective form; if confirmed not defective, no issue. However if scope unknown and central database incomplete, must not allow "under defective form" if records incomplete. Need "may not assume all or no subjects were affected when records incomplete." So implement site-wide hold on new enrollment and nonurgent research interventions until each site confirms the actual signed consent version, and for any 4.2 or unconfirmed/unknown, hold until board approves corrected materials and re-consent if needed. For confirmed 4.1/4.3, nonurgent research interventions may continue? Need maybe if risk disclosure correct in those versions. But there is also "approved protocol identifies risk and requires in consent"; v4.1/v4.3 contain it. So yes, those subjects have valid consent as to risk. But sponsor may need "immediately stop new enrollment" across board? Rule says stop new enrollment under defective form. If a new subject hasn't signed any consent or signed current correct version? If no consent form? For new enrollment, if using v4.2? We know version 4.2 defective, but v4.3 contains risk. Could continue enrolling using v4.3? But since scope unknown, perhaps immediate hold on all new enrollment until inventory of consent forms at sites confirms which version is being used. Since five-site study, likely one site(s) have v4.2 stock; need verify. If any site has only v4.3, can continue? The rule says stop new enrollment under defective form; if using correct form, no. But safest immediate all holds pending verification. User asks "immediate enrollment and intervention holds" likely answer: pause all enrollment and nonurgent interventions until site-level confirmation and corrected materials approved; do not rely on assumption. Need include this. Need address emergency approval of corrected materials: Need prepare corrected consent version 4.4? Since v4.3 contains it, but if sites have v4.2 versions, use corrected materials. Need submit to ethics board tomorrow; include corrected consent and maybe "re-consent script/summary" for completed subjects? The "central ethics board can convene emergency review tomorrow." Need "within five business days" report to ethics board, within seven calendar days device regulator. Since discovery Wednesday 10 a.m.; tomorrow Thursday board meeting; must report before? Rule says report within five business days and seven calendar days. We should include reporting timeline: Wednesday discovery = day 0? Need count: report to ethics board no later than five business days after discovery: if discovery Wednesday, business days Thursday? Need be careful. "Within five business days after discovery" often count next business day? Need not assume? Need give exact dates maybe. We don't know calendar date but can say five business days from Wednesday 10 a.m., likely by end of next Wednesday? Let's calculate: If discovered Wed, "within five business days" maybe Wednesday counts? Business days: Thu, Fri, Mon, Tue, Wed = five; by end of next Wednesday. If counting begins next day, Thursday is day 1; five business days by following Wednesday? Actually Thursday, Friday, Monday, Tuesday, Wednesday = five; no difference. But if include Wednesday as Day 0? no. Need define. For regulator within seven calendar days: by next Wednesday? From Wednesday 10:00 a.m., seven calendar days: following Wednesday at 10:00 a.m. (or end of day? Need deadline; use no later than next Wednesday). However they also asked "board within five business days" and regulator within seven calendar days. Need report both maybe board immediately before emergency review? Should not wait. Since board can convene tomorrow, report now? "immediately notify board and regulator? The facts says not yet notified. Rule says material noncompliance report within deadlines. Should notify ethics board immediately (certainly before emergency review tomorrow) and device regulator as soon as possible, within 7 calendar days. The board review doesn't satisfy regulator. Need maybe notify board today/now, not wait for emergency meeting. Since "central ethics board emergency review tomorrow" but "has not yet notified board" - do notice now, request emergency review. Also if local sites have faster reporting requirements per approved plan, sites must comply; none supplied but should verify. Need re-consent of subjects awaiting intervention: enrolled subjects not completed interventions must be re-consented on approved corrected form before next nonurgent intervention. For confirmed 4.2 awaiting implant: hold; after board approves corrected materials, re-consent in person/with proper process; no email alone; must give opportunity to ask questions and decide; document signed correct version; no backdating. For unknown version subjects scheduled for implantation: verify actual consent version before any nonurgent intervention; if unknown or 4.2, hold and re-consent. For confirmed 4.1/4.3, no re-consent? Since already disclosed risk; can continue? But maybe need offer updated info? Rule 5 says "An enrolled subject who has not completed study interventions must be re-consented on an approved corrected form before the next nonurgent intervention." Does this apply to all enrolled subjects who haven't completed interventions, even if signed v4.3? No, "re-consented on an approved corrected form" due to omission. But if a subject signed v4.3 that includes risk, they already have correct consent; no need re-consent. But need verify v4.3 was approved? It contains risk. But wait if v4.3 later approved? It is a version that contains risk. Is it approved? The facts say approved protocol requires risk; version 4.3 contains it, presumably approved? Need okay. The "defective form" is 4.2. So no. But the problem says "Twelve subjects are scheduled for implantation during next 72 hours. Four are confirmed version-4.2. The consent versions for eight are unknown." Need address 8 unknown: cannot proceed until site verifies. They may be v4.2. Need stop all 12? Since unknown for 8; hold all scheduled implants until each actual version confirmed; for 4.1/4.3 may possibly proceed even before corrected materials? But maybe because "until an ethics board approves corrected materials" might be read as all nonurgent research interventions under the defective form; if confirmed not 4.2, no defect. But if some are v4.1/4.3, they could proceed if no other issues. But the immediate hold all scheduled implants due to scope unknown until verification is prudent and probably required by "may not assume all or no subjects were affected." Also if a scheduled subject signed v4.1/4.3, can their implant proceed while board hasn't approved corrected materials? There's no need for corrected consent for that subject. But if the protocol and other consent forms still valid, yes. But could there be an issue: The "corrected materials" approval to be sought; the board might require hold all? We can plan: hold all nonurgent interventions at sites with v4.2 or unknown; if site confirms no v4.2 and all affected? Hmm. Need "Care and safety follow-up that must continue." Continue medically necessary care and safety follow-up, including routine safety visits? The fact says "Six other subjects need routine safety visits this week. No urgent medical intervention depends on research schedule." Need maybe routine safety visits are care/safety follow-up? They should continue? Rule 3 says medically necessary care and safety follow-up must continue. A "routine safety visit" can be safety follow-up and not a "research intervention"; likely continue. Need not withhold care. If safety visits are required by protocol, but are nonurgent research interventions? Hmm "routine safety visits" could be protocol-required assessments; should they continue as safety follow-up? The question: "Medically necessary care and safety follow-up must continue. A sponsor may not abandon subjects or withhold care merely to preserve a study pause." So yes, continue all medically necessary care, including management of adverse event and any clinically indicated follow-up; continue protocol-required safety monitoring if needed to prevent harm, even if not "research intervention"? But "nonurgent research interventions" under hold. Need distinguish. Safety visits are not implantation; can continue because they are safety follow-up. Also continue subject access to care, emergency unblinding? Not relevant. Need mention adverse event known nerve weakness: ensure subject receives appropriate care, follow-up until resolution, and now disclosure? Wait subject experienced after implantation and resolved; not told before implantation that risk was known. Need address notification to subject? The rules: subject who completed intervention must receive new risk info when may affect safety follow-up or willingness to permit continued data use. But also a material risk omitted from consent; when discovered, should notify affected subject? The rules specifically re-consent for not completed, notice/consent choices for completed. The known nerve-weakness event: It is an adverse event in a v4.2 subject, should have been reported through ordinary safety channel; now in context of consent noncompliance, is the subject "completed interventions"? likely yes. Need notify subject that risk was known and omitted? Rule 6: "A subject who completed interventions must receive new risk information when it may affect safety follow-up or the subject's willingness to permit continued data use." This subject experienced the risk, resolved after 4 days; new risk information "temporary nerve weakness known 3% risk" may affect willingness to permit continued data use? It is safety relevant. Need disclose to subject, apologize? Not necessarily. Could say provide corrected risk information, answer questions, offer re-consent/continued data use choices if study includes follow-up/data use. If the event was already reported through ordinary safety channel to regulator/board? If required by adverse event reporting, continue; but ensure noncompliance separately reported. Need not withhold info. Consent cannot be backdated. Need "Notice and consent choices for subjects who completed intervention." The facts: "A subject who completed interventions must receive new risk information when it may affect safety follow-up or the subject's willingness to permit continued data use. Consent may not be backdated or recreated as though valid disclosure occurred earlier." Need plan for all subjects confirmed/identified as v4.2 who have completed interventions (the nerve-weakness subject and any others). Provide a written notification/risk disclosure (maybe "addendum" or "important new information") describing omitted risk, and afford them choices: (a) continue in follow-up/data use; (b) decline further data use, if legally/ethically feasible; maybe request withdrawal; (c) ask questions; for those with ongoing safety follow-up, still provide medically necessary care irrespective of data choice. Need maybe get documentation/consent to continued data use? Rule says "must receive new risk information when it may affect ... willingness to permit continued data use." It doesn't explicitly say "re-consent" or "must obtain affirmative consent" for completed subjects. But "Notice and consent choices" in assignment suggests provide notice and choices; maybe need get acknowledgment/documentation of choice. Need avoid backdating. If they completed interventions and data already collected, can ask permission to continue using data; if no response, maybe board decides? Need say do not delete or destroy data; document choice; if subject objects, flag and follow ethics board/regulator. Existing consent form remains valid for data already collected? Hmm. Need "Treatment of previously collected data." Rule 7: not automatically discarded; ethics board decides continued use after considering risk, subject wishes, scientific integrity, nature noncompliance. So don't destroy or freeze? Preserve; seek ethics board determination for use of data from v4.2 subjects. If subjects decline, honor preferences consistent with law and protocol; no unilateral deletion? Need preserve data pending board. Need maybe include data lock: quarantine? No, "not automatically discarded"; board decides. Need preserve, don't alter; can continue storing securely. Need not discard. Also if data from unknown subjects? Need identify via records. Need "Specific records needed to determine affected population." Need version-controlled records and direct site confirmation; cannot assume. Need gather: - Master consent form version history (v4.1, 4.2, 4.3) with approval dates/IRB approvals, clean copies showing risk paragraph in 4.1/4.3 and omission in 4.2; document-conversion error details and metadata. - For each of 120 subjects: site identifier, subject ID, enrollment date, actual consent form version signed, date signed, signed PDF/paper original, site logs (consent log, delegation log), IRB approvals, amendments, protocol version. - For each signed PDF not uploaded: request upload/site confirm. - For the 62 unknown: central database has enrollment dates but not consent version; several signed PDFs not uploaded. Need direct site confirmation: each site reviews source documents, site screening/enrollment logs, signed consent forms, maybe site-maintained consent tracking spreadsheet. - Document the version in use at each site at relevant dates; which version was active/stock at time each subject signed; maybe if signed form doesn't include version number? Need determine through signatures/date and site form version log. - E-timestamp of database uploads; audit trail for PDFs. - Correspondence/emails between sponsor and sites about form distribution/version. - Adverse event/safety reports for nerve weakness (safety channel, report dates). - Records of any prior consents for subjects who may have re-consented? Hmm. - Maybe regulatory/IRB approvals for v4.2? The fact says approved protocol requires risk, but v4.2 omitted due to conversion error. Need determine whether ethics board ever approved v4.2? The approved consent may have been 4.1 or 4.3; if 4.2 was mistakenly used without approval? Need include approval status of each version. If v4.2 was not approved, that's more noncompliance. But facts say "approved protocol identifies risk and requires that risk in consent." "Consent-form version 4.2 omitted" maybe it was used; likely approved? Need not assume. Need determine if v4.2 was approved by ethics board and whether deviation from approved protocol. Include "whether v4.2 was ever approved/used despite approval; if not, additional reporting." But not necessary? Need include because version-controlled records needed. Need "Preservation, privilege, and the proposed PDF replacement." Need: - Issue litigation hold/preservation notice to sponsor/staff/IT/sites. Preserve all versions, signed forms, site logs, timestamps, communications, data records. No overwriting, deletion, or destruction. - Explicitly reject CSO's proposal to replace v4.2 PDFs with v4.3 in database. This would destroy/spoliate evidence and falsify records; violates preservation and audit trail; could violate consent documentation; could expose sponsor to regulatory/criminal sanctions. Instead, keep v4.2 PDFs and audit trail; add new corrected version v4.4? If v4.3 exists, but to correct v4.2 for re-consent use maybe need create corrected version? Since v4.3 contains paragraph; but if the consent form version 4.3 includes risk, perhaps use it? But if v4.2 was defectively used, the corrected materials could be version 4.3 (already approved) or new 4.4 to make clear amendment. The assignment says "Emergency approval of corrected materials"; "corrected form" maybe need v4.4. Need think. The fact says "consent-form version 4.2 omitted the nerve-weakness paragraph because of a document-conversion error. Version 4.1 and version 4.3 contain it." The site investigators propose continuing scheduled implants while sending explanatory email afterward. Chief wants replace v4.2 PDFs in database with v4.3 "so the file is clean." NovaCrest can convene central ethics board for emergency review tomorrow. It has not notified board/regulator. Need "Emergency approval of corrected materials." Could emergency approve version 4.3? But version 4.3 already exists; maybe it is not "corrected" from 4.2? It contains risk, so maybe use version 4.3. But if v4.3 was approved and current, how could v4.2 be used at site? Perhaps a document conversion error created v4.2 that was then approved? Need not know. For re-consent, the board should approve a corrected version for subjects who signed 4.2. Since v4.3 already contains risk but may not be the "same form" as v4.2 except omission? The safest is to prepare a new version (e.g., 4.4) that contains the nerve-weakness paragraph, clearly states it supersedes v4.2 for re-consent, and maybe notes the omitted information. But the "corrected materials" could be v4.3 if v4.3 has been approved and the form is otherwise appropriate. Yet if v4.3 is an existing version, using it for re-consent of v4.2 subjects might be acceptable; but to create clean audit trail and avoid confusion, likely submit corrected form version 4.4? Need include "corrected consent form (new version, not overwrite v4.2; if v4.3 is the approved correct version, use it only if appropriate; otherwise prepare v4.4)." The problem wording "emergency approval of corrected materials" implies need get board approval. Need plan sequence: On Wednesday, after discovery: stop, preserve, notify board, request emergency review. Prepare corrected informed consent form including risk paragraph, maybe "version 4.3/4.4" and re-consent script. Then tomorrow board emergency review; after approval, implement. But if v4.3 already contains risk and is approved, perhaps no need for board approval for v4.3? But rule 2 says until ethics board approves corrected materials. We need board approve corrected materials. Submit v4.3? Hmm. Need "the concrete sequence over next 72 hours and seven days, without assuming the unknown 62-subject scope." Need produce timeline. Need include immediate actions day 0; next 24-72 hours; within five business days; within seven calendar days; ongoing. Need not assume unknown 62 are affected; treat as unconfirmed and gather evidence. Let's systematically think through all requirements and possible ethical/legal issues. Let's identify "research rules" as if governing law are given. Need apply to facts. Rule 1: valid informed consent before research intervention; disclose material risks identified in approved protocol. v4.2 omitted; therefore no valid informed consent for that risk for subjects who signed v4.2 before implantation. Need stop. Rule 2: Immediately stop new enrollment and nonurgent research interventions under defective form until ethics board approves corrected materials. "under the defective form" maybe only v4.2; but because unknown, perhaps need stop all nonurgent research interventions until each subject's consent version confirmed? We should phrase nuanced: - Immediately (as of 10:00 a.m. Wednesday) direct all sites to: * Suspend all new enrollment into the study until site consent-version inventory confirms that no prospective subject will be consented on v4.2 and any defective forms are quarantined. * Suspend all nonurgent study interventions for any subject whose signed consent version is v4.2 or not yet confirmed. This means the 4 confirmed v4.2 and 8 unknown scheduled implants must not proceed until verification and, if needed, approved corrected consent/re-consent. For the 8 unknown, schedule/case won't proceed until site confirms signed version; if confirmed v4.1/v4.3, then evaluate whether that version was approved and contains risk; if yes, may proceed (assuming other protocol requirements met). However, since the board emergency review will occur tomorrow, it may be simpler to hold all nonurgent implants until after emergency review to allow a uniform corrected process. But "without assuming all/no" means not allow unconfirmed; for confirmed v4.1/4.3, if all records direct, not necessarily under defective form. But the need for "scope remains unknown" maybe we shouldn't say all 12 must wait if 8 unknown? Need state: "A site-wide hold on all nonurgent interventions is the only compliant approach until actual consent versions are confirmed, because proceeding with an unknown subject risks a nonurgent intervention under a defective consent. Once a subject is confirmed by source record to have signed v4.1/v4.3, the sponsor may consider allowing that specific intervention to resume, but it must first ensure the v4.2 form is not the one in use and that no institutional hold is broader." That balances. - For "new enrollment": similar: pause new enrollment until each site confirms no v4.2 form is in use and correct form available; after corrective action maybe resume if board approves. The rule specifically says stop new enrollment under defective form; but because a new subject could be handed v4.2 if stock remains, immediate pause and quarantine defective forms. After all sites confirm v4.2 quarantined and v4.3/4.4 available, new enrollment may resume after board approval? Rule says "until ethics board approves corrected materials." So maybe wait until board approval before new enrollment. But if v4.3 already approved, maybe maybe not. But safest: no new enrollment until emergency board approval and sites confirm corrected form. Actually "immediately stop new enrollment ... until an ethics board approves corrected materials" - even if v4.3 exists, board approval of corrected materials is required. We'll say hold all new enrollment until board approves corrected forms and sites confirm use. Need "Care and safety follow-up that must continue": - Do not stop medically necessary care or safety follow-up for enrolled subjects; this includes the nerve-weakness subject, any complications, and routine safety visits where they are for subject safety. But do not perform nonurgent research interventions (e.g., implantation) under defective consent. - If "routine safety visits" are protocol-required and do not pose more than minimal risk? Are they "nonurgent research interventions"? Need decide. Rule 3 says medically necessary care and safety follow-up must continue; maybe all "safety follow-up" including protocol-required safety assessments should continue to ensure no missed harms. The fact includes "Six other subjects need routine safety visits this week." The assignment asks "Care and safety follow-up that must continue." So answer: continue routine safety visits, adverse-event monitoring, and any clinical follow-up; only the implantation procedures (nonurgent research interventions) hold; schedule visits are not withheld; no subject abandoned. But if a safety visit includes research-only data collection, is that "nonurgent research intervention"? The rule says "safety follow-up must continue" and sponsor may not withhold care; but it doesn't explicitly say research-only safety data collection must continue. "Medically necessary care and safety follow-up must continue." A "routine safety visit" may include both clinical and research assessments. Need continue those necessary for safety; for non-safety research data collection, if under defective consent maybe pause? Need think. The instruction: "3. Medically necessary care and safety follow-up must continue. A sponsor may not abandon subjects or withhold care merely to preserve a study pause." Thus, "safety follow-up" should continue even if it's part of research, because it's safety. Nonurgent research interventions (like implantation) are paused. Safety visits this week should occur. In the plan, say: "Protocol-required safety visits and AE follow-up should continue on schedule, even though implantation is paused." Also if any of the six require an implant? no, routine safety. If urgent medical intervention needed, it's not "research schedule" and can proceed. Need "Ethics-board and regulator reporting clocks": - Board: must report within five business days; but because emergency review requested, notify immediately, no later than today; full written report maybe by deadline. Need not wait. The "within five business days" after discovery: due date maybe Wednesday next week? Need state: "Assuming Wednesday is day zero, the deadline is no later than the close of the fifth business day (the following Wednesday if no holidays)." Let's calculate. If discovery Wednesday 10:00 a.m., "within five business days" often means by end of five business days after discovery; if you count Wednesday as day 1? Let's examine common regulatory: "within 5 business days after the sponsor becomes aware" means 5 business days after the day of discovery? If discovery Wednesday, if day after is day 1, deadline end of next Wednesday? Let's compute inclusive vs exclusive. Need avoid ambiguity by saying "not later than five business days after discovery; on these facts, submit before the emergency meeting and in any event by [the fifth business day]." Maybe no exact calendar date needed. But assignment asks "reporting clocks." Could identify "five-business-day report to ethics board and seven-calendar-day report to device regulator begin Wednesday 10:00 a.m." Use "no later than five business days" and "no later than seven calendar days." Good. But maybe "material consent noncompliance" to board "within five business days" and regulator "within seven calendar days *after discovery*." Need say if report due sooner due to local site plans; verify. Need not assume faster. But also "A site must make any faster local report required by its approved plan; no faster local period is supplied here." So ask sites to check IRB/regulatory approvals for local reporting deadlines and comply. Notify central board immediately anyway. Regulator notice: Should we notify immediately rather than wait seven days? The rule says within seven calendar days; but "material consent noncompliance" to device regulator within seven calendar days. We can say report before seven calendar days; because known material risk omitted and known AE, do not wait; file as soon as possible. Is there any requirement to report to regulator before board? No. Need "Emergency approval of corrected materials": - Prepare corrected consent form: restore nerve-weakness risk (3% temporary nerve weakness) in plain language; remove v4.2 defect; clearly identify version number/date; include maybe "Important information form" for completed subjects. Need submit to central ethics board for emergency review tomorrow. Need not wait for local site boards? The central ethics board approves corrected materials; but site-specific local requirements? "central ethics board" in facts; assume central. Need incorporate local institutional requirements? Could say obtain central board approval; after approval distribute to sites; no site may use before written approval. Need maybe if sites have local IRBs? Not given. Need mention. Re-consent of subjects awaiting intervention: - After board approval, for subjects with confirmed v4.2 or unconfirmed? Once confirmed v4.2, must re-consent on approved corrected form before next nonurgent intervention. Re-consent must be genuine: in person (unless approved remote), provide copy, answer questions, allow time, document signature/date, no backdating; no email-only. If subject refuses re-consent, no further nonurgent research intervention; continue care/safety follow-up; honor data wishes. For unknown 8: verify actual consent; if v4.2, same. If confirmed v4.1/v4.3, no re-consent needed for omitted risk; but if institution/board requires all implants pause until review, follow that. If subject has not signed any valid consent for some other reason, address. Need "Notice and consent choices for subjects who completed intervention": - For all subjects identified as v4.2 who have completed implants? Need determine who completed intervention. Provide "notification of corrected risk information" perhaps before/during board approval? The rules may require after discovery "must receive new risk information when it may affect safety follow-up or willingness to permit continued data use." Does that need happen immediately, not wait for board approval? Probably after discovery, as soon as practical, but corrected materials need board approval for re-consent of incomplete. For completed subjects, the consent form was defective but no future interventions; notification can be provided. Need not re-consent before research intervention; it's a notice. Could use an "approved corrected risk summary" maybe needs board approval? Rule 2 says stop until ethics board approves corrected materials; but for completed subjects, maybe board should approve notification too? The central ethics board must approve corrected materials, perhaps including notice to completed subjects. The assignment says "emergency approval of corrected materials"; "Notice and consent choices for subjects who completed intervention." Need sequence likely after board approves corrected materials, notify completed subjects. But is there any need to wait? We can say prepare notification, submit with corrected materials, then send after approval. However safety concerns? The risk is temporary nerve weakness; no urgent safety issue requiring disclosure before board. But "must receive new risk information when it may affect safety follow-up or willingness to permit continued data use." If the subject is still in follow-up, prompt notification after board approval is appropriate. If the risk has safety implications, maybe send an interim notice sooner? But corrected materials need approval; could send factual notice before approval? We should avoid unapproved materials. The rule only requires consent form approval, not notification; but to be safe, seek emergency approval of both. Need maybe schedule within 72 hours. The assignment sequence next 72 hours: within 24h notify board; emergency review tomorrow; after approval contact subjects. Good. Potential issue: Should completed subjects whose signed version unknown also receive notice if unknown? Need determine if v4.2. For the 62 unknown, cannot assume; need verify. For subjects confirmed v4.1/v4.3 no new risk info needed? They were told. For known v4.2 completed subjects, yes. For unknown completed? Need verify before notice? Actually if records unknown, you cannot know whether they need notice. But to be safe, maybe send notice to all subjects whose version cannot be confirmed? But rule 9 says may not assume all/no. Does sending notice to all unknown harm? It may be confusing; but "do not assume all or no subjects affected when records incomplete" means you cannot say all 120 affected; you must determine. However, you also cannot withhold notice from possibly affected subjects while determining. The duty to disclose material risk may require notice to subjects who may have signed v4.2 if records incomplete? Need nuance. The assignment says "without assuming the unknown 62-subject scope." So for unknown 62, need determine through records. But if records are incomplete, can we continue to wait to give notice? Rule 9 says determine scope through version-controlled records and direct site confirmation. It doesn't say can't treat unknown as potentially affected. For immediate holds, treat unknown as potentially at risk. For notice to completed subjects, likely once direct site confirmation identifies affected subjects, notify them. But if signed PDF not uploaded, direct site confirmation may take time; should the sponsor notify possible affected subjects before confirmation? Hmm. The rule requires report within 5 business days and maybe re-consent before next nonurgent intervention; not necessarily immediate notice to all unknown. For "known nerve-weakness event", known affected definitely. For unknown, gather records to determine. But if a subject scheduled in next 72h is unknown, hold until confirmed. If a subject completed and unknown, we need maybe send notice when discovered? The "must receive new risk information when it may affect safety follow-up or the subject's willingness to permit continued data use." It says "A subject who completed interventions must receive new risk information when it may affect..." If the subject's consent version is unknown, do we know they completed under defective form? No. But they may have; the missing risk could apply. The law may require providing new risk information to all subjects who might have been under the defective form? Rule 9 says "may not assume all or no subjects were affected" so "not assume no" means must investigate and perhaps take protective action for possible affected. For disclosures, if records incomplete, you can give a "safety notice" to all subjects whose version cannot be confirmed? Is that "assuming" they are affected? It's cautious; but could be seen as over-notification. We need decide. The assignment "without assuming the unknown 62-subject scope" may mean don't decide all 62 are affected; identify actual versions. But "several signed PDFs not yet uploaded" - after collecting them, you can know. The plan should say: treat unconfirmed subjects as "potentially affected" for purposes of holds and safety; but do not state in regulatory reports that 62 are affected until verified. Use records to narrow. Notify confirmed affected; if after diligent investigation a subject cannot be confirmed as v4.1/4.3, consult board and likely provide notice because cannot rule out. Need mention. Need "The known nerve-weakness event." Need plan: - The event was already reported via ordinary safety channel; continue ensuring it was reported to relevant safety database. It doesn't satisfy consent-noncompliance reporting; report separately. - For the subject: provide clinical follow-up/resolved; make sure no residual deficit; disclose now that temporary nerve weakness was a known protocol risk and that the v4.2 consent form omitted it; apologize? Legal answer not need but can mention factual candor. Document disclosure. Provide contact for questions. Obtain acknowledgment. The subject's data use? Since completed intervention, provide choice; if willing, continue; if not, flag; board decides. - In reports to board/regulator, include this event as evidence of materiality/harm: one v4.2 subject experienced the omitted risk after implantation and was not informed. Report as adverse event per safety reporting (if deadlines) and as part of noncompliance report. - Need consider "ordinary safety channel" maybe the event was reportable to regulator under AE reporting; don't confuse. Need say "continue/verify SAE/AE reporting obligations separately; this consent noncompliance report is in addition, not instead." Need "Preservation, privilege, and proposed PDF replacement" robust: - Issue immediate preservation notice to all sponsor and site staff: no deletion/alteration of v4.2 PDFs, signed consent forms, site logs, timestamps, communications, data records. In particular, do not replace v4.2 PDFs with v4.3; do not delete/re-upload; do not modify metadata. The correct action is to preserve v4.2 and the audit trail, and add a new version/amendment. If necessary, snapshot database and restrict permissions. - The CSO's proposal is impermissible and potentially spoliation/falsification. It would hide the noncompliance, destroy evidence, and mislead board/regulator. It could violate consent documentation and recordkeeping requirements; may convert regulatory violation into fraud; must reject in writing. - Legal privilege: separate privileged legal analysis from operational facts. The sponsor may request counsel review and label privileged communications; but privilege cannot excuse reporting, preserving, or candor. The facts of the omission, version numbers, dates, and AE must be reported. Do not put privilege label on factual records to avoid disclosure. Legal hold communications may be privileged but factual evidence not. - If legal advice is prepared, separate file; no need to disclose privileged analysis to board/regulator unless required; but factual candor and documents must be available. - Need maybe not mention "attorney-client privilege" if outside counsel? Yes. Need "Specific records needed": Need perhaps include "consent version and approval matrix" with columns. Need be thorough. Let's craft. Need "concrete sequence over next 72 hours and seven days, without assuming unknown 62-subject scope." Let's outline final answer perhaps sections: 1. Immediate actions (Wednesday 10:00 a.m. onward): - Activate response team; issue hold/preservation. - Stop new enrollment and all nonurgent research interventions? Need exact: * All sites: suspend new enrollment and all scheduled implants/procedures until each potential subject's actual consent version is confirmed and, for v4.2/unconfirmed, board-approved corrected consent and reconsent. * At minimum, the 12 scheduled implants (4 confirmed v4.2 + 8 unconfirmed) must not proceed. Do not proceed with any unconfirmed as v4.1/v4.3 unless source signed form is reviewed. * Quarantine v4.2 consent forms and any forms of unknown version; remove from use. * Continue safety visits and medically necessary care. - Notify ethics board immediately and request emergency review tomorrow. Notify regulator? Maybe "as soon as possible and within 7 calendar days" but perhaps report to regulator immediately too? If no reason to wait, yes. Need "board/regulator clocks" perhaps first contact today. We can say "The five-business-day and seven-calendar-day clocks start now; do not wait." 2. Investigation to determine scope: - Direct each site to confirm for every enrolled subject: * actual consent version signed; date; site; whether any later reconsent; upload signed PDF. * which version(s) were in use at site during enrollment windows; whether v4.2 stock remains; who downloaded/printed/converted forms; document-conversion error. - Build subject-by-subject reconciliation for all 120: v4.1, v4.2, v4.3, unknown. For the 62 unknown, obtain from site source docs. Do not infer from dates; confirm. For 8 scheduled unknown, priority. - Determine affected population = confirmed v4.2 signers; plus unknown pending confirmation. Do not assume 62 or 0 affected. 3. Corrective materials and approvals: - Prepare corrected consent version (e.g., v4.4) or use approved v4.3? Need recommend new version. Maybe: * Because v4.3 already contains the risk, if it was properly approved and is identical except for the defect, the board may approve its use as the corrected form; however, for audit clarity and to avoid confusion with v4.2, create a new corrected version (v4.4) marked "corrects v4.2" and submit it. Use v4.3 only if the board directs. Actually if v4.3 is current approved version, why did v4.2 exist? Maybe there is version confusion. Need include "corrected consent (new version) that restores the missing paragraph; if v4.3 is already approved and appropriate, it may serve, but the safer course is an explicit new version/amendment so there is no ambiguity that it is a correction." This is nuanced and acceptable. * Include an "Important Information About Your Participation" notice for completed subjects, explaining omission and options. * Submit to central ethics board for emergency approval at tomorrow's meeting; no use before written approval. If central board approves only corrected form, use; if requires additional site approvals, obtain. 4. Reporting: - Notify central IRB/ethics board now, not just within 5 business days; full report by deadline. - Notify device regulator within 7 calendar days; preferably sooner. Include: - facts: v4.2 omitted 3% temp nerve weakness; version error; discovery Wednesday; numbers confirmed/unconfirmed; action taken; one event; corrective steps; data preservation. - local site reporting deadlines: instruct sites to check and comply; document. - If report is due to sites/IRBs faster, follow. 5. Re-consent and notices: - For v4.2 or unconfirmed subjects pending implant: * Schedule after board approval; contact subject, arrange in-person/telehealth? "informed consent process" typically in person; if allowed, maybe. Provide corrected consent; discuss risk; answer questions; allow time; sign/date; provide copy; no backdating. * If subject refuses: no implant under research; continue care; record; honor withdrawal/data choice. * For 8 unknown, first verify. If v4.2, same. If confirmed v4.1/v4.3 and no board hold, can proceed if approved; but if not, wait. - For completed v4.2 subjects (including nerve-weakness subject): * Provide new risk info and options. This can occur after board approval (or immediately if board approves notice). Explain that temporary nerve weakness is known 3% risk and was accidentally omitted; apologize? maybe "factual candor." * Ask whether they wish to continue permitting use of previously collected data and ongoing follow-up; offer option to decline/withdraw data if permissible. Document choice. No backdating; do not pretend consent was valid. Continue medical care regardless. * If no response, follow up; do not assume consent to continued data use? Hmm. Existing consent may permit data use; but after new information, if no response, maybe continue data use? The rule says "must receive new risk information when it may affect ... willingness to permit continued data use." It doesn't explicitly require opt-in for previously collected data; but assignment says "consent choices." Need address. Maybe say: "For future data collection, obtain affirmative consent/acknowledgment after notice. For already collected data, do not destroy; seek subject preference and board decision. If a subject objects, segregate that subject's data and do not use without board/legal authority." This is prudent. - For completed subjects with unknown version: after investigation, if can't confirm v4.1/v4.3, treat as possibly affected and provide notice; consult board if records remain incomplete? Need mention. But "without assuming unknown 62" maybe phrase: "Do not state that all 62 are affected. But for subjects whose version cannot be confirmed after direct site review, the investigator/sponsor should treat them as potentially affected for risk-disclosure purposes and ask the board how to proceed; do not rely on 'probably not affected.'" This complies. 6. Data: - Preserve all data; no deletion/overwrite. For previously collected data from v4.2 subjects, do not discard; place on "preserve" status. Request central ethics board to determine continued use/research after considering risk, subject wishes, scientific integrity, nature; subject wishes honored where possible. If consent form omission invalidates consent? Rule says not automatically discarded; board decides. So no unilateral destruction. - If a subject withdraws consent/declines data use, segregate data and stop future use; but preserve underlying records for regulatory/legal purposes. 7. 72-hour / 7-day sequence: Need provide a step-by-step timeline: - Day 0 (Wednesday, within hours): * 10:00 a.m. discovery. Immediately issue verbal/written hold and preservation. * Confirm no implants today? If scheduled within next 72 hours, stop them. Continue safety visits. * Notify IRB/ethics board; request emergency review. Begin regulator draft; notify regulator? maybe. * Issue site data request; quarantine v4.2/unknown forms. * Instruct no PDF replacement. * Begin subject-level reconciliation of 120; priority for 12 scheduled. - Day 1 (Thursday, within 24-48 hours): * Emergency ethics board meeting; submit corrected consent and notice. Obtain approval if possible. * Site confirmation for scheduled implants: identify versions for 12. If any v4.2/unconfirmed, do not implant until reconsent; if v4.1/4.3, okay except any board restriction. * Draft/submit board report (if not already) and regulator report (if ready). - Days 2-3 (Friday/Saturday? Need no weekends? The next 72 hours from Wednesday includes Thu/Fri/Sat. If surgeries maybe weekdays. Need not assume weekends. Use "during the next 72 hours." * After board approval: for v4.2/unconfirmed scheduled subjects, contact, arrange re-consent; no implant until signed corrected form. Continue verifying all subjects. * Complete/continue uploads of signed PDFs; but preserve v4.2. Need not "upload" maybe use original records. * Send notice to completed v4.2 subjects (after approval) with options. - By end of five business days: * File full central ethics board report, including scope findings and corrective actions. If all 120 not reconciled, say unknown and provide plan; do not guess. - By seven calendar days: * File regulator report; include final/available scope; if incomplete, provide interim and commitment to supplement. * Continue re-consent/notices as records confirm. - Ongoing: * Board determines data use; continue care; preserve records; respond to regulator inquiries. Need "without assuming unknown 62-subject scope" in sequence: - In reports: "Confirmed affected: 4? Actually only 4 confirmed v4.2 scheduled but total v4.2 confirmed at Site A 38; plus 62 unknown; 20 confirmed v4.1/4.3. So confirmed affected = 38 plus maybe any completed? Site A says 38 subjects signed 4.2; likely all v4.2? Wait Site A confirms 38 subjects signed version 4.2. So confirmed v4.2 = 38. Twenty subjects at other sites signed 4.1/4.3. Remaining 62 unknown. Need not confuse with 4 scheduled implants. In reports, confirmed affected 38? But if 38 at Site A includes some scheduled? Yes likely. Actually Site A confirms 38 subjects signed version 4.2; this is a confirmed count. Therefore affected population known at least 38; plus unknown 62 may include more. Need mention: "The confirmed affected population is 38 signed v4.2 at Site A; the 62 unknown are unconfirmed, not presumed affected. The four scheduled v4.2 implants are within that 38; eight unknown are within the 62." Wait Site A says 38 subjects signed v4.2. Total 120 - 38 - 20 = 62 unknown. So at least 38. But are all 38 "enrolled subjects" maybe signed consent but not necessarily all underwent intervention; some may be awaiting, some completed. Need determine. Could there be other v4.2 at other sites among 62? yes unknown. The "confirmed v4.2" count is 38 at Site A. In reporting, "so far, 38 subjects are confirmed to have signed v4.2; 20 confirmed signed correct versions; 62 remain under verification." This is not assuming unknown 62. Need ensure "without assuming unknown 62-subject scope" maybe they don't want to say all 62 affected. Instead classify. Need think about "new enrollment" if there are subjects who have not signed consent at all? Since 120 enrolled, new enrollment not yet? Stop any new enrollment. If a prospective subject may sign v4.3, can they enroll? Rule 2 says stop new enrollment until board approves corrected materials. We'll hold all new enrollment. Need "nonurgent research interventions under the defective form" - If an intervention is urgent/medically necessary, can proceed without re-consent? Rule 3 says medically necessary care must continue; if a subject needs urgent implant? Fact says no urgent medical intervention depends on research schedule. But generally, if urgent medical intervention is independent of research, it can proceed as care; if it is research intervention? Hmm. We can state "Nothing in this hold prevents emergency/medically necessary treatment; if an implantation is needed urgently for medical care outside research, follow emergency consent provisions and care standards, but not label it as a research procedure under the defective form." But not needed. Need "site investigators propose continuing scheduled implants while sending explanatory email afterward" - This is clearly noncompliant because an email after an intervention cannot cure lack of prospective informed consent; material risk must be disclosed before intervention, and corrected consent form must be approved before use. Need reject. We should mention in plan: "No email-after; no 'consent by hindsight'; no backdating." Also "explanatory email afterward" could be acceptable as notification for completed subjects? No, not for scheduled implants. Need explicitly say. Need "chief scientific officer wants staff to replace version 4.2 PDFs in database with version 4.3 'so file is clean.'" Need explicitly reject as spoliation and falsification; direct that version 4.2 be retained and database snapshot; no replacement. Need "Privileged legal analysis may be separated from operational fact gathering, but privilege does not excuse required reporting or factual candor to oversight bodies." We need maybe state: "Use a factual investigation team to gather facts; legal counsel can advise in parallel. Do not place facts solely in privileged communications. Regulatory reports must be truthful and complete; no privilege assertion to withhold the omission, version 4.2, AE, or corrective actions." Good. Need "exact stop, report, investigation, and re-consent sequence" perhaps should not just list; need order. Let's consider if there are potential conflicts between "report to ethics board within five business days" and "emergency approval tomorrow". Need maybe "do not conflate report with request for correction; the emergency review request should disclose the noncompliance and ask for approval; the formal report follows within deadline." Good. Need maybe "material consent noncompliance" definition? The v4.2 omission is material noncompliance because it omitted material risk and invalidates consent. Need report to board and regulator. Good. Need perhaps "device regulator" not named; use "competent device regulator" or "FDA" if applicable? The problem says "device regulator"; answer generic. Need perhaps "central ethics board" vs "IRB" use "ethics board." Need "valid informed consent before any research intervention." For the 4 confirmed v4.2 scheduled implants, no re-consent yet; no implant. For eight unknown, if no signed version confirmation, no implant. The 20 confirmed v4.1/v4.3 maybe not under defective form, but if any were scheduled and if "v4.3" contains risk, okay. However, all 12 scheduled include "Four are confirmed version-4.2. The consent versions for eight are unknown." It doesn't say any are confirmed v4.1/4.3. So all 12 likely hold because unknown or v4.2. Good. Need "six other subjects need routine safety visits this week" - Are those "nonurgent research interventions" that should stop? Need careful. The answer maybe "Routine safety visits should continue as safety follow-up, but do not perform data collection beyond what is needed for safety while consent question unresolved." But if the visit includes research questionnaires? Need perhaps say: "Protocol-required safety visits for monitoring of subject safety should continue; if a planned visit includes elective research-only procedures not necessary for safety, defer those until a corrected consent is in place." This is nuanced. But fact says "routine safety visits"—we can continue. Need maybe "No scheduled implant may proceed; routine safety visits are not implantation, so they can proceed." Good. Need "ethics board decides continued use after considering risk, subject wishes, scientific integrity, and nature of noncompliance." Need in data section. Need perhaps "do not withdraw approved protocol? The sponsor could suspend? Not needed. Let's think through possible legal obligations around "discovering" and "reporting": "When a sponsor discovers that a consent form omitted a material risk, it must immediately stop new enrollment and nonurgent research interventions under the defective form until an ethics board approves corrected materials." Does "under the defective form" mean only v4.2, so if a subject signed v4.1/4.3, no hold. However "The site investigators propose continuing scheduled implants while sending explanatory email afterward." Need tell them "No, all scheduled implants using v4.2/unknown must stop; even if v4.1/v4.3, ensure they're using correct version." Good. Need "notify board within five business days": Since board emergency review tomorrow, if we submit corrective materials, that is effectively a report? But formal report requirement still. Need maybe "submit a noncompliance report before emergency review if possible; at minimum provide to board at meeting." Need "regulator within seven calendar days": Does "after discovery" include weekends/holidays? yes calendar days. Need maybe "if day falls on weekend/holiday, file no later than next business day"? Regulatory deadlines usually "within 7 calendar days" no next business day maybe if falls weekend? We can avoid. Use "no later than seven calendar days after Wednesday; calculate with calendar; if a different rule applies follow." Need "emergency approval of corrected materials" "central ethics board can convene emergency review tomorrow." Need not wait for final scope; corrected materials independent. Need "the corrected form should be used for re-consent at all sites; if local site approvals required, coordinate." Need "one version-4.2 subject experienced temporary nerve weakness resolved after four days" maybe need consider "this event must be disclosed to the board/regulator as an adverse event and as evidence of noncompliance; there is no need to stop ordinary safety reporting; ensure the AE report includes consent version and omission? Maybe." Need perhaps "the event should be assessed for whether it meets reportability under device regulation (serious adverse event? Temporary nerve weakness resolved in 4 days; maybe not serious, but could be adverse device effect; check)." But not necessary. Need "the site investigators propose continuing scheduled implants while sending explanatory email afterward" - Need "the protocol of re-consent before next nonurgent intervention is not fulfilled by email after; the email may be an adjunct to notice but not consent." Need "the central database identifies enrollment dates but not consent version; several signed PDFs not yet uploaded." Need "Do not rely on dates to infer version because version could change over time; direct site confirmation required." Good. Need "version-controlled records and direct site confirmation. It may not assume all or no subjects were affected when records are incomplete." We should include "For unknown 62, after direct confirmation, classify them; if records are truly missing, don't assume; escalate to board and perhaps do not use data until resolved? The board decides. Do not simply exclude." Great. Need maybe "new enrollment" with currently unenrolled subjects: "not enroll any new subject until all sites have confirmed only corrected consent forms are in use, board approval, and any re-consent process implemented." Good. Need potential "risk of temporary nerve weakness is known in approved protocol but was omitted from form"; Should we revise protocol? no. Need maybe "Consent form version 4.2 omitted because of document-conversion error" Could be a "breach of Good Clinical Practice" and "could invalidate informed consent." Need not. Let's decide final answer structure. Desired oververbosity 5, but user asks detailed plan. Need produce moderately detailed but not too long. We can include sections with bullets. We need maintain "exact stop, report, investigation, and re-consent sequence." We can write "Ordered Plan" with steps 0-7. Good. Let's draft final answer: --- **Immediate response (Wednesday 10:00 a.m.)** 1. Activate hold: - Issue written and oral directive to all sites: suspend all new enrollment and all nonurgent research interventions. Quarantine v4.2 forms and any unconfirmed forms. Do not use email-after consent. Do not replace PDFs. - Specifically, the 12 scheduled implants must not proceed unless and until the signed consent version is confirmed and, if v4.2, corrected board-approved consent is signed. The four confirmed v4.2 are held. The eight unknown are held pending verification; they may proceed only if source record shows v4.1/4.3, and not before verifying no hold. For confirmed v4.1/4.3 subjects, no v4.2-based hold is needed once confirmed, but if any site/board imposes broader hold, follow. Maybe phrase "because version status is unknown for eight, no implant in that group may go forward until the actual signed form is reviewed." This is exact. - Continue safety visits/medically necessary care; don't stop AE follow-up. No urgent implant is research schedule. 2. Preserve: - Litigation hold and data snapshot. Explicitly reject replacing v4.2 with v4.3; preserve v4.2 PDFs and audit trail; no deletion/modification. Separate privilege. 3. Notify: - Immediately notify ethics board, request emergency review tomorrow. Do not wait; submit a brief noncompliance notice now and fuller report by deadline. - Begin regulator report; file no later than seven calendar days after discovery and preferably sooner. Check local site reporting. **Investigation/records** Build a subject-level consent-version matrix: - For each of 120 subjects: site, subject, actual signed version, signed date, source form; if re-consented, all versions; site consent log; version distribution log; database upload metadata. - For 62 unknown: obtain signed PDFs/originals from sites, verify. "Do not infer from enrollment dates." - 20 confirmed correct and 38 confirmed v4.2; unknown 62 remain unconfirmed. Need maybe this classification. Actually "Site A confirms 38 subjects signed version 4.2" means confirmed. We should not list "at least" maybe. Let's include "Current confirmed counts: 38 v4.2, 20 v4.1/v4.3, 62 to verify." But is that true? Yes. But "without assuming unknown 62 scope" doesn't mean don't count; okay. **Corrective materials and board** - Prepare corrected consent version (new version, e.g. 4.4) restoring risk. If v4.3 is already approved and appropriate, the board can approve its use as the correction; but new version is safer. The "corrected form" should be clearly marked supersedes v4.2. - Prepare notice/decision form for completed subjects explaining omission and choices. - Submit to central board tomorrow; no use until written approval. After approval, distribute to sites. **Re-consent before next nonurgent intervention** - For v4.2/unconfirmed subjects awaiting intervention: * No nonurgent intervention until corrected consent signed. * Contact after board approval, provide corrected form, in-person discussion, questions, signature/date. No email substitute, no backdating. * If refuses, no research intervention; continue care/safety; document. - For unknown: verify version; if v4.2, re-consent; if confirmed v4.1/v4.3, no re-consent for this issue. **Notice/choices for completed** - Identify completed v4.2 subjects (including nerve weakness subject) once confirmed. Send board-approved notice (or approved corrected consent? maybe not full re-consent) stating omitted risk; explain that risk occurred at rate 3%, that v4.2 accidentally omitted it; provide PI contact; ask if they consent to continued data use/follow-up or object; document choices. - Medical care continues regardless. No backdating/recreation. - For completed unknown subjects, do not assume they are affected; but if after diligent review cannot confirm version, treat as potentially affected and inform/board? Need maybe phrase. **Previously collected data** - Preserve all. No automatic discard. Request board determine continued use. Segregate data of subjects who object/withdraw and await board/legal direction. If subject wants withdrawal, honor where feasible while preserving records. **Regulatory reports** - Board within 5 business days, likely no later than end of next Wednesday if counting standard; but since emergency review tomorrow, provide before then. - Regulator within 7 calendar days from Wednesday; include confirmed/unconfirmed counts, not assumed; include AE; corrective actions; preservation. Submit supplement as investigation completes. **Sequence next 72 hours / 7 days** Need maybe table: Day 0: - 10:00 hold/preserve; no implants; notify board; request emergency review; direct sites to verify 12 scheduled subjects; no PDF replacement; continue safety visits. Day 1: - Emergency board review; submit corrected consent and notice; get approval if possible. Report to board? formal. If board imposes conditions, implement. Complete verification for as many scheduled subjects as possible; for scheduled v4.2/unconfirmed, schedule re-consent after approval; no implants until signed. Day 2-3: - Re-consent subjects before any scheduled implant; send notice to completed v4.2 subjects; continue record collection; maybe file regulator report if ready before deadline. By 5 business days: - File full board noncompliance report; include subject-level scope (confirmed/unknown), corrective actions. By 7 calendar days: - File regulator report; include all known facts; supplement as unknown resolved. Ongoing: - Board decision on data; preserve records; monitor AEs; continue care; cooperate. Need ensure "six routine safety visits this week" in sequence: Day 0-3 "allow the six routine safety visits to proceed as safety follow-up; if any component is purely research and not safety-related, defer until consent resolution." Maybe include. Potential issue: "emergency approval of corrected materials" before "report to regulator" maybe board can approve after report? The sequence includes notifying board tomorrow; okay. Let's think of edge cases: - If the 62 unknown include subjects who signed no consent? Hmm. But "enrolled subjects" likely signed some consent. Need direct record confirms. If no signed consent at all, that's additional serious noncompliance. Include "If any subject cannot be documented as having signed any approved consent, treat separately and report." But not necessary. Could include in investigation: "also confirm existence of a signed consent for every subject." Good. - If a subject signed v4.2 and is now completed, "completed interventions" maybe no future nonurgent interventions. Need still provide notice. But if they have follow-up visits, rule 6 says new risk information may affect willingness to permit continued data use; maybe need get choice before further data use. If follow-up visits are research interventions? They are not "interventions" maybe data collection. But if they have not completed all study procedures (e.g., follow-up visits are part of study), are they "enrolled subject who has not completed study interventions"? Hmm. "An enrolled subject who has not completed study interventions must be re-consented on an approved corrected form before the next nonurgent intervention." If follow-up visits are study procedures but not interventions? Could require re-consent before any further protocol-specific nonurgent procedure. Need in plan: "For any v4.2 subject whose protocol participation is not complete—including those with future follow-up visits that involve research procedures—treat as not completed to the extent there are any remaining nonurgent research interventions/procedures; obtain corrected consent before such procedures. For those truly completed, provide notice and choice." Good. The fact says "completed interventions" but not necessarily completed follow-up. Need mention. The rule 5 says "An enrolled subject who has not completed study interventions must be re-consented on an approved corrected form before the next nonurgent intervention." It doesn't say "all study participation"; "interventions" perhaps implantation. But if a subject completed implant but has follow-up visits, do they need re-consent before safety visit? The safety visit is not an intervention? Could be "research intervention" if it involves procedures. The rule 6 covers "completed interventions" receiving new risk info. The safest: if any future protocol procedure is nonurgent and not medically necessary, get corrected consent before it; if it's medically necessary/safety follow-up, continue but also notice. Need include. Need perhaps "routine safety visits" are not "urgent medical interventions" but are safety follow-up; should continue because Rule 3. But if they are "research interventions" (blood draw etc.) under defective consent, can they continue? Safety follow-up is mandated. Need not overanalyze. Potential issue: "No urgent medical intervention depends on the research schedule." So all implants are elective/nonurgent. "Routine safety visits" are not "urgent medical intervention" but are safety. Rule 3 says safety follow-up must continue. Good. Need maybe "known nerve-weakness event" "not told before implantation that this was a known risk." Does that mean the event was also an "unanticipated problem" because subject couldn't anticipate; report to IRB promptly maybe under "unanticipated problems involving risks" not just consent noncompliance. But the facts governing law only says report material consent noncompliance to board/regulator. Need perhaps say "also evaluate whether the nerve-weakness AE meets separate adverse-event/unanticipated-problem reporting requirements; complete those reports according to applicable deadlines." Good. Need maybe "material risk" = 3% temporary nerve weakness. Need not provide medical advice. Let's perhaps draft final answer in coherent legal memo style. Need maybe mention "This plan assumes the central ethics board is the reviewing IRB/ethics committee and the device regulator is competent authority." Not necessary but okay. Need perhaps "within five business days and seven calendar days" exact due date: We can say "If Wednesday is Day 0, the board report is due by the end of the fifth business day thereafter and the regulator report by the same time on the seventh calendar day (next Wednesday, unless a holiday)." Need be precise: Discovery on Wednesday at 10:00 a.m. If "within five business days" means by end of next Wednesday? Let's calculate again with examples: - If report due within 5 business days after discovery and discovery Wed. If "after" excludes discovery day: - Thu day 1, Fri day 2, Mon day 3, Tue day 4, Wed day 5. Due end of Wed. - If include discovery day as day 1: - Wed 1, Thu 2, Fri 3, Mon 4, Tue 5. Due end of Tue. Hmm, ambiguity. Need avoid exact unless necessary. The problem asks "reporting clocks", not "exact date." We can say "five business days from Wednesday means no later than the end of the fifth business day after discovery; calculate according to the institutional rule. If the institution counts the discovery day as day one, that would be Tuesday; if not, Wednesday." But maybe too much. Better "not later than five business days after discovery (i.e., on these facts, by the close of the fifth business day following Wednesday; check local counting)." This shows awareness. But the user likely expects "five business days" as given. We can simply state "within five business days of Wednesday, not by tomorrow's review." Maybe enough. Need "within seven calendar days after discovery" - exactly next Wednesday if no holidays? Seven calendar days after Wednesday: Thu 1, Fri 2, Sat 3, Sun 4, Mon 5, Tue 6, Wed 7. So by Wednesday. If using "within 7 calendar days after discovery" maybe due by end of next Wednesday. We can say "by the following Wednesday at the latest" but if there are holidays. Need "assuming standard calendar." That may be acceptable. But "without assuming" not relevant. Could say "Seven calendar days from Wednesday is the following Wednesday; if the deadline falls on a nonbusiness day, check applicable rule, but do not rely on extension unless regulator provides." Hmm. Need maybe "regulator within seven calendar days after discovery" not "within seven days after sponsor becomes aware"? yes. Need "central ethics board emergency review tomorrow" - If not notified yet, can they convene tomorrow if not notified? no, need notify today. Need perhaps "If board won't approve corrected materials at emergency review, hold remains." Yes. Need "site-specific local report required by approved plan; no faster local period supplied; instruct sites." Include in reporting section. Need "Do not let the 62 unknown be recorded as affected in regulatory filings unless confirmed." Include in "investigation." Potential issue: "Site A confirms that 38 subjects signed version 4.2." Is that "confirms" but not "signed PDFs uploaded"? Site A confirmation maybe direct site confirmation; okay. We need maybe "Site A must provide the signed forms and site log to verify, not just oral confirmation." The rule says direct site confirmation, but records needed. The problem says "Site A confirms"; but sponsor needs records. We'll say "obtain source documentation from Site A for the 38." Need maybe "Site A confirms 38 subjects signed version 4.2" could mean all 38 v4.2, not unknown. Need not assume all are affected? It is confirmed. Good. Need "central database identifies enrollment dates but not consent version; several signed PDFs not yet uploaded." To know the 62, use site source. Need not rely on database. Good. Let's think about "re-consent" and "consent choices for subjects who completed intervention" if a completed subject declines continued data use: Does that invalidate previously collected data and require deletion? Rule 7 says board decides continued use after considering subject wishes. It doesn't say delete. We can say "do not destroy; segregate; await board/regulator." Good. Potential issue: "Privileged legal analysis may be separated from operational fact gathering, but privilege does not excuse required reporting or factual candor to oversight bodies." Need perhaps "direct that the internal investigation report be prepared with factual findings available to board/regulator; legal advice can be in separate privileged memo." Nice. Potential issue: "document-conversion error" maybe if v4.2 was used at multiple sites but only Site A confirmed? Need know which sites used v4.2. Maybe "confirm whether v4.2 was distributed to sites other than A" because other sites may have used it but not reported? Actually 20 subjects at other sites v4.1/4.3 and 62 unknown; among those 62, some at other sites may have v4.2. Need include. Need perhaps "site log and signed PDFs not yet uploaded" "Central database identifies enrollment dates but not consent version" - The sponsor may need to "lock" database? Maybe "snapshot the database to preserve timestamps." Include. Let's think if "known material risk omitted from one consent-form version" means there are three versions; "v4.3 contains it" maybe if v4.3 is after v4.2, the current version is correct. The document-conversion error means v4.2 lacked paragraph; v4.3 corrected it? But v4.3 could have been created before or after; if v4.3 contains risk, maybe no "emergency approval" needed? Wait if v4.3 is already approved, why not simply use v4.3 for new consents? The rule says when sponsor discovers defect, stop until ethics board approves corrected materials. If v4.3 is already approved and contains risk, perhaps the board has already approved corrected materials. But the fact states "Version 4.1 and version 4.3 contain it." The defect version is 4.2 only. Maybe v4.3 is not "corrected materials" for the v4.2 omission if v4.3 existed before discovery? It contains risk. But if v4.3 was approved, no omission. However, because v4.2's "document-conversion error" may have occurred in between, it may be an unapproved version; the correct consent is v4.3. Then continuing implants under v4.3 could be allowed? But the rule 2 says "until an ethics board approves corrected materials" in context "defective form." If no one is under defective form after v4.2 is removed, why need board approve v4.3? But the sponsor discovered a material consent noncompliance involving 38 confirmed subjects; the law may treat the "corrected materials" as the re-consent form for those subjects. The existing v4.3 could be used for new consents but the board should be notified and approve re-consent process. The assignment explicitly says "NovaCrest can convene the central ethics board for an emergency review tomorrow" and "Emergency approval of corrected materials." So we should proceed with board approval. Need perhaps "If v4.3 is already approved and contains risk, the sponsor should not necessarily wait for board approval to use v4.3 for future consents if not defective; but the safest and required-by-problem approach is to submit it as corrected materials and get board approval." Need include to not overstate. Maybe phrase: "Because v4.2 is the defective version, v4.3 may already satisfy the substantive disclosure; nevertheless, submit it (or a new version) to the board for approval as the corrected/current consent and for the re-consent process. The hold remains until that approval." Good. Potential issue: "Immediate stop new enrollment" if the current correct v4.3 is available, could continue enrollment in other sites? The law says stop new enrollment "under the defective form"; not necessarily all. But scope unknown. We'll hold all. Need maybe "A narrower hold is legally insufficient until you know whether v4.2 is in use at each site." Good. Need perhaps "do not conduct nonurgent interventions for confirmed v4.1/4.3 subjects if the v4.2 issue suggests the board might require a new form for all; but a sponsor can continue for confirmed correct absent board order. However, because 'scope remains unknown' and there may be a broader institutional hold, maybe hold all? Let's decide final wording: - "All nonurgent research interventions are paused pending verification of the consent version for the specific subject. This is not because every subject is presumed affected; it is because the sponsor cannot know which scheduled interventions are under 4.2 until source records are reviewed. Once a subject is confirmed to have signed v4.1 or v4.3, the specific v4.2-based hold does not apply to that subject, unless the ethics board or sites impose a broader hold." This is logical and complies with rule 9. New enrollment likewise paused until form inventory confirms no v4.2 in use and board approves corrected form. Good. Need perhaps "routine safety visits" under this "all nonurgent research interventions paused" might be nonurgent; but they are safety follow-up and should continue. We can define: "The pause covers nonurgent research procedures/interventions such as implantation; it does not cover medically necessary care, safety follow-up, AE monitoring, or visits needed to prevent deterioration." Good. Potential issue: "routine safety visits" could be "research interventions" but not "nonurgent" maybe necessary. We'll say "The fact that they are routine does not make them optional if they are safety/medically necessary." Hmm maybe. Need maybe "urgent medical intervention" not affected; if one scheduled implant became medically urgent, decide as medical care, not research. But problem says none. We can say "Nothing in this plan authorizes delay of urgent care; if a subject needs urgent medical intervention, it should be provided outside the research protocol as clinically indicated and documented, with emergency consent requirements as applicable." But maybe "outside research protocol" not needed. Include? Maybe in care section. Let's think about "device regulator" deadlines and "report material consent noncompliance" within seven calendar days. Should the sponsor notify the regulator "within seven calendar days" but if the subject AE was reported through ordinary safety channel, perhaps regulator already knew about AE but not omission. Need "the AE report may have been filed; the consent noncompliance is separate and should be reported to regulator with reference to AE report." Good. Need "site must make any faster local report required by approved plan" maybe "instruct each site PI to review local IRB/institution policies and make required reports immediately; sponsor should not instruct site to delay local reporting." Good. Need "Preservation, privilege, and PDF replacement" perhaps in immediate response and investigation. Need maybe "do not 'clean' files; the existence of v4.2 in the database is the truth; removing it would be falsifying records." Good. Let's consider potential "valid informed consent" in v4.2 signed subjects: Is their consent void? Rule 7 says data not automatically discarded; but consent invalid? The defect may mean no "valid informed consent before research intervention." However, in re-consent, cannot backdate; a subject may choose to continue with corrected consent. But does the prior intervention become retrospectively authorized? No, but data may still be used if board allows. Need maybe say "The omission makes the prior consent materially inadequate; re-consent cannot retroactively cure the prior failure, but it can authorize future procedures and data use." Good. Need maybe "subjects awaiting intervention" if they re-consent, must sign corrected form before next nonurgent intervention. Does this allow them to proceed if board approved corrected form and they sign, even if no additional waiting period? Usually yes, after consent process and as protocol requires. But if "the subject must be given time to consider" maybe include "reasonable opportunity" not necessarily 24h? Need not. Need "corrected materials approved" - if board approval is for corrected form v4.4, but v4.3 contains risk, perhaps "the board may approve v4.4 for re-consent and v4.3 for new enrollment." We don't need be too prescriptive. Need perhaps "the known nerve-weakness event" could affect subject's willingness to continue data use; maybe need "offer independent clinician? If there is a conflict of interest? Not given. Not necessary. Need "reporting clocks" and "investigation" maybe "notify regulator now" is not required but "as soon as possible" within 7 calendar days. Could someone argue notifying regulator before board might be required by device regulation? The rule specifically says within seven calendar days. We can say "The seven-day clock starts now; do not wait until the last day. Because materiality is clear, an initial report should be made promptly, and certainly by the deadline." Good. Need "the central ethics board emergency review tomorrow" - Does "board" need to know before review? Yes. We can include "send the notice today; supply materials for tomorrow's meeting." Good. Need "without assuming unknown 62-subject scope" maybe in reporting and holds: "For the 62, the sponsor should not state to the board/regulator that all 62 were affected, nor that none were affected. It should describe them as 'under verification' and provide a timeline for verification." Nice. Need maybe "for the 8 scheduled with unknown consent versions, no implant even if database has enrollment date and no uploaded PDF; cannot infer." Good. Let's maybe prepare a draft final answer: --- **MEMORANDUM / PLAN** **A. Immediate holds and ongoing care** Within minutes of discovery (now): 1. Issue a written hold to all sites: - Stop all new enrollment. - Stop all nonurgent research interventions, including all 12 scheduled implants, until the signed consent version for each subject is verified. - For the 4 confirmed v4.2 subjects, no implant may occur until board approves corrected consent and the subject signs it. - For the 8 unknown, no implant may occur until the actual signed form is reviewed. If the actual form is v4.2, re-consent; if v4.1/v4.3, document and may proceed only if no broader board/site hold. - Quarantine v4.2 forms and any unverified forms; remove from use. 2. Continue care: - Do not stop safety visits, AE follow-up, or medically necessary care. The six routine safety visits may proceed as safety follow-up. If any visit includes non-safety research-only procedures, defer those until consent issue resolved. - Continue to monitor and manage the temporary nerve weakness subject. **B. Preservation and no spoliation** - Issue preservation notice to all sponsor staff, sites, IT, CROs: preserve all consent versions, signed forms, PDFs, logs, timestamps, emails, database audit trails. - Snapshot database. Do not replace v4.2 PDFs with v4.3. The CSO proposal is rejected; it would be spoliation/falsification and could convert the noncompliance into fraud. - Separate privileged legal advice from factual investigation; privilege is not a basis to withhold facts from regulators/board or to delay reporting. **C. Investigation to determine scope** - ... matrix ... **D. Ethics and regulatory reporting** - ... clocks ... Need maybe order "reporting" before "corrective materials"? The assignment asks "exact stop, report, investigation, and re-consent sequence"; but final can order as sequence. Need perhaps include "Within five business days" report: "The report should include: version history, confirmation counts (38 v4.2, 20 v4.1/v4.3, 62 pending), corrective actions, re-consent plan, the nerve weakness AE, and preservation steps." Good. **E. Corrected materials and approval** - Prepare corrected consent version; submit to board; no use before approval. "The corrected form must disclose the 3 percent temporary nerve weakness risk in the same or clearer language as approved protocol." Good. - The board should also approve the notice/choice form for completed subjects. "Once approved, use only that version until further amendment." Good. **F. Re-consent and notices** - Before next nonurgent intervention: * For v4.2/unconfirmed not complete: after approval, re-consent. In person, no email-only, no backdating. If refuses, no research intervention; continue care. * For confirmed v4.1/v4.3: no re-consent required based solely on this defect. - Completed subjects: * Provide approved notice of omitted risk and choices. For nerve weakness subject, directly disclose known risk and omission; provide contact; document. * Ask whether continue data use/follow-up; if objection, segregate and board decides; continue care. **G. Data use** - Preserve data; no deletion. Board decides future use based on factors. Subject choices honored. "If v4.2 subjects decline continued data use, segregate but do not destroy." **H. 72-hour/7-day sequence** Need maybe table. Let's make concise. Potential issue with "regulator report by seven calendar days" maybe "file initial report before seven days, not wait for full scope; if still unknown, provide interim and supplement." Need include. Need maybe "The central ethics board's emergency approval tomorrow is not a substitute for the formal report to the ethics board; the report and approval are separate." Include. Potential issue "local site report" maybe after board approval? Actually local report may be before; instruct sites. Need perhaps "corrective work must not overwrite audit trail" in preservation. Good. Let's think if "re-consent of subjects awaiting intervention" includes "the 12 scheduled implants during next 72 hours; after board approval tomorrow, if 8 unknown not verified yet, perhaps some may be v4.2; no implant until verification and reconsent. If verification takes longer, reschedule. No implants under unknown. This may mean none of 12 proceed within 72 hours unless verification and re-consent occurs; okay." Need maybe "Because emergency board review is tomorrow, the earliest implantation could occur is after board approval and after re-consent; in practice likely after 72 hours." Good. But if no v4.2 form and no re-consent needed, could occur. We'll not overpromise. Need maybe "six routine safety visits this week" if they require consent? Could say "safety visits should proceed on their scheduled dates; only research-specific procedures not needed for safety should be deferred until consent resolution. If the visit is purely safety monitoring, it is not part of the hold." Good. Need perhaps "the central database identifies enrollment dates but not consent version; several signed PDFs have not yet been uploaded." In investigation, "do not use the database as complete; it is not source." Good. Potential issue "approved protocol identifies a 3 percent risk of temporary nerve weakness and requires that risk in consent." Maybe consent forms v4.1/v4.3 contain it, but if v4.2 was used at Site A, maybe Site A's local ethics approval may be different. We need "verify each site's approved version." If v4.2 was approved by central board despite omission? If the board approved v4.2 without risk, then the protocol requirement was not met; report. If version 4.2 was not actually approved, then additionally "used consent without approval" and report. Need include in investigation: "obtain approval history for each version; identify whether v4.2 was ever approved and whether v4.3 was approved and active." Good. Need perhaps "the sponsor must determine scope through version-controlled records and direct site confirmation. It may not assume all or no subjects were affected when records are incomplete." We should mirror in final: "Do not assume 62 affected; do not assume only 38 affected." Good. Let's ensure final answer not too verbose but with enough detail. Desired oververbosity 5. User's assignment asks detailed, so maybe oververbosity 5. We can produce about 2,500-4,000 words? Maybe too much. Need keep concise but comprehensive. We can use bullets and headings. Let's aim around 2,000-3,000 words. But final oververbosity 5 maybe 1,800. Need maybe not overdo. Since legal plan, comprehensive. Let's draft final content now. Potential issue: "within five business days" and "seven calendar days" in sequence with emergency board tomorrow: If board emergency review tomorrow, should formal board report be submitted before/at meeting. We'll say "Immediately send a notice; the formal report must be filed by the five-business-day deadline, but because the emergency review is tomorrow, the board should receive the full noncompliance package in advance of that meeting." Good. Need maybe "regulator" not notified yet: "Do not wait for board approval to notify regulator; board approval is only for consent materials, not a precondition to regulatory reporting." Good point. Need "the known nerve-weakness event" maybe if subject has not been told before implantation but event resolved; "There is no justification to withhold that information now; disclose it as part of the corrective notice. Do not characterize the event as expected if the subject was not informed?" Hmm. The event was "temporary nerve weakness" which is known; report as "expected but undisclosed to subject due to consent omission." Good. Let's now formulate final answer with "Ordered Plan" maybe: --- Start with "This plan assumes that no other faster site-specific reporting deadlines apply; sites should check." Good. Potential "No urgent medical intervention depends on research schedule" - If none, all implants are nonurgent; hold. Good. Let's write final: ``` Immediate hold: - All new enrollment... - All nonurgent research interventions... ``` Need "new enrollment" maybe if "all new enrollment" is too broad? We can phrase "All new enrollment is paused pending site confirmation of which consent form is in use and board approval of corrected materials; this is the only way to ensure no prospective subject is consented on v4.2." Good. Need "if a subject has confirmed v4.1/v4.3 and is scheduled for implant, can they proceed before board approval?" We'll phrase "Once verification is complete and the only forms in use are corrected, the v4.2-based hold would not apply to that subject. However, the sponsor should not allow any surgical procedure to proceed under an unverified or defective consent; if the subject's version is confirmed correct, the sponsor may proceed, but if the board or site imposes a hold until after its review, follow it." Good. Need "preservation and PDF replacement" maybe before "investigation" because immediate. We'll put after immediate or before. User asks "Preservation, privilege, and proposed PDF replacement" maybe after records. Let's follow assignment order? The assignment asks "Provide an ordered plan addressing:" with bullet list; we can align. Maybe final answer heading order: 1. Immediate enrollment and intervention holds 2. Care and safety follow-up 3. Investigation and records to determine scope 4. Reporting to ethics board and regulator 5. Corrected materials and emergency approval 6. Re-consent of subjects awaiting intervention 7. Notice/consent choices for completed subjects 8. Previously collected data 9. Known nerve-weakness event 10. Preservation, privilege, and PDF replacement 11. Concrete 72-hour/7-day sequence That addresses all. Good. Need maybe "emergency approval" before "reporting" maybe reporting should happen before approval. But assignment order not strict. We can include "reporting clocks" after immediate, while "corrected materials" later. Fine. Let's think if "site investigators propose continuing scheduled implants while sending explanatory email afterward" is addressed where? In re-consent section: "rejected." Need mention "No email-after; no delayed disclosure as substitute for prospective consent." Good. Need "consent may not be backdated or recreated as though valid disclosure occurred earlier" in re-consent/notice. Need include. Need "the ethics board decides continued use after considering..." in data section. Good. Need "not assume all/no affected" in investigation and reporting. Good. Potential issue: "A signed PDF has not yet been uploaded" — If signed PDFs exist but not uploaded, need collect. But "not uploaded" could refer to database; "signed PDF" in original. We need "obtain from sites, not rely on central database." Good. Potential issue: "Site A confirms 38 subjects signed version 4.2" — Need "site confirmation" not enough? It says "confirms" but actual records needed. We'll say "obtain signed forms and consent logs supporting confirmation." Good. Potential issue: "Twenty subjects at other sites are confirmed to have signed version 4.1 or 4.3." The "other sites" maybe no v4.2? Could be. Not need. Need "specific records needed to determine affected population" list perhaps not too long, but enough. We'll include bullet list with "for each subject" etc. Good. Let's ensure final answer uses "central ethics board" and "device regulator" not "IRB/FDA" to match. We can use "board" and "regulator." Let's write final final answer with moderate detail. Need maybe "within five business days" in sequence: - "Day 0 Wednesday: discovery; Day 5 next Wednesday (unless holiday) etc." maybe we can avoid exact. But the user asked "reporting clocks." We can state: "Five-business-day board deadline runs from Wednesday; if the day of discovery is counted as day zero, the deadline is end of the fifth business day thereafter. Seven-calendar-day regulator deadline likewise runs from Wednesday. Do not wait for either deadline; because materiality is now known." This is enough. Need perhaps "board report within five business days" but emergency review tomorrow: "The emergency approval submission should itself include enough facts to constitute a noncompliance notice; the separate formal report can follow by the five-business-day deadline." Good. Need "site must make faster local report" - include "instruct each site to identify and honor any local reporting deadlines; no local faster period was given, but they must not be delayed by the sponsor's central timeline." Need maybe "privilege and reporting" in preservation section: "Do not put operational facts in a privileged memo and then claim privilege to avoid disclosure; the facts are not privileged merely because counsel is copied." Good. Let's now compose final. Potential final text: --- **Ordered Plan** **1. Immediate holds** As of Wednesday 10:00 a.m., the sponsor should: - "new enrollment pause..." - "protocol intervention pause..." - "quarantine..." - "do not destroy..." Need "do not send explanatory email after implant" maybe. **2. Safety/medical care** ... **3. Investigation/records** ... **4. Ethics/regulator reporting** ... **5. Corrected materials and board approval** ... **6. Re-consent** ... **7. Completed subjects** ... **8. Data** ... **9. Nerve-weakness event** ... **10. Preservation/privilege/PDF** ... **11. Sequence** ... This is fine. Let's ensure "known nerve-weakness event" not duplicate but okay. Need perhaps "central ethics board emergency review tomorrow" in sequence "tomorrow" but if discovery Wednesday, "tomorrow" is Thursday. We'll use "Day 1 (Thursday)." But if no date, okay. Need maybe "within 72 hours" from Wednesday 10 a.m. includes Thursday-Saturday; "The scheduled implants in next 72 hours are held; because board review is tomorrow, if a subject signs corrected consent after approval, the implant may be considered at the earliest after that; otherwise reschedule." Good. Need perhaps "If any scheduled implant is a v4.1/v4.3 subject, no re-consent; but the site must first verify from source, and if central/site hold continues until all subjects verified, follow that hold." Good. Let's now ensure final answer not too repetitive. Maybe there will be some repetition but okay. Potential issue: "The sponsor must report material consent noncompliance to the central ethics board within five business days and to the device regulator within seven calendar days after discovery." Does "report material consent noncompliance" require immediate report to board before emergency meeting? We'll say "immediately notify board and regulator of occurrence; formal report within deadlines." Good. Need maybe "The board and regulator reporting clocks are not tolled by ongoing investigation." Include. Need perhaps "A site must make any faster local report required by its approved plan; no faster local period is supplied here." In reporting section. Need perhaps "If v4.2 was approved by board with omission, board itself may need to review; if not approved, additional noncompliance." We'll include in investigation: "Obtain approval history for each version; determine whether v4.2 was ever approved, and whether v4.3 was the approved version. If v4.2 was never approved, that is an additional reportable deviation." Good. Need perhaps "corrected materials" if v4.3 contains risk "the correction might be to return to v4.3; however, for subjects who signed v4.2, a new re-consent version/ addendum is advisable." Hmm. We can write "The board should approve the form that will be used for re-consent. If v4.3 is otherwise the approved correct version, using it as the corrected form may be acceptable, but a distinct corrected version/amendment is the clearer way to document the correction." Good. Need maybe "re-consent" "approved corrected form" if subject has cognitive impairment? Not in facts. No need. Potential issue: "six other subjects need routine safety visits this week" "routine safety visits could be considered nonurgent research interventions under the hold, but safety follow-up must continue. To be safe, conduct the clinical/safety portions; defer non-safety research data collection." We can include in "care and safety" and sequence. Good. Let's draft final answer now in polished style.